Adjuvant Chemo After Nephroureterectomy May Aid Survival in
For patients undergoing radical nephroureterectomy (RNU) for pT3/T4 and/or pN+ upper tract urothelial carcinoma (UTUC), adjuvant chemotherapy (AC) use is associated with an overall survival benefit, according to a study published online in the Journal of Clinical Oncology.

The researchers found that after RNU, 762 (23.42%) and 2491 (76.58%) patients with pT3/T4 and/or pN+ UTUC received AC and observation, respectively. Median OS was significantly longer for AC versus observation (47.41 vs 35.78 months) in inverse probability of treatment weighting (IPTW)-adjusted Kaplan-Meier curves. For AC versus observation, the 5-year IPTW-adjusted rates of OS were 43.90% and 35.85%, respectively. AC correlated with a significant OS benefit in IPTW-adjusted Cox proportional hazards regression analysis (hazard ratio, 0.77). Across all subgroups this benefit was consistent, with no significant heterogeneity of treatment effect.

Read more at: http://www.renalandurologynews.com/urology/upper-tract-urothelial-carcinoma-adjuvant-chemotherapy-survival-advantage/article/630087/
Like
Comment
Share